<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Heliyon</journal-id><journal-id journal-id-type="iso-abbrev">Heliyon</journal-id><journal-id journal-id-type="pmc-domain-id">2992</journal-id><journal-id journal-id-type="pmc-domain">heliyon</journal-id><journal-title-group><journal-title>Heliyon</journal-title></journal-title-group><issn pub-type="epub">2405-8440</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10826739</article-id><article-id pub-id-type="pmcid-ver">PMC10826739.1</article-id><article-id pub-id-type="pmcaid">10826739</article-id><article-id pub-id-type="pmcaiid">10826739</article-id><article-id pub-id-type="pmid">38293424</article-id><article-id pub-id-type="doi">10.1016/j.heliyon.2024.e24333</article-id><article-id pub-id-type="pii">S2405-8440(24)00364-5</article-id><article-id pub-id-type="publisher-id">e24333</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Pharmacokinetic analysis of placental transfer of ritonavir as a component of paxlovid using microdialysis in pregnant rats</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Sun</surname><given-names initials="CK">Chung-Kai</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Lee</surname><given-names initials="WH">Wan-Hsin</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Yang</surname><given-names initials="MH">Muh-Hwa</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Tsai</surname><given-names initials="TH">Tung-Hu</given-names></name><email>thtsai@nycu.edu.tw</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff3" ref-type="aff">c</xref><xref rid="aff4" ref-type="aff">d</xref><xref rid="aff5" ref-type="aff">e</xref><xref rid="cor1" ref-type="corresp">&#8727;</xref></contrib><aff id="aff1"><label>a</label>Institute of Traditional Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan</aff><aff id="aff2"><label>b</label>Institute of Clinical Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan</aff><aff id="aff3"><label>c</label>Graduate Institute of Acupuncture Science, China Medical University, Taichung 404, Taiwan</aff><aff id="aff4"><label>d</label>Department of Chemistry, National Sun Yat-Sen University, Kaohsiung 804, Taiwan</aff><aff id="aff5"><label>e</label>School of Pharmacy, Kaohsiung Medical University, Kaohsiung 807, Taiwan</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8727;</label>Corresponding author. Institute of Traditional Medicine, College of Medicine, National Yang Ming Chiao Tung University, 155, Li-Nong Street Section 2, Taipei 112, Taiwan. <email>thtsai@nycu.edu.tw</email></corresp></author-notes><pub-date pub-type="collection"><day>30</day><month>1</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>10</day><month>1</month><year>2024</year></pub-date><volume>10</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">453936</issue-id><elocation-id>e24333</elocation-id><history><date date-type="received"><day>27</day><month>7</month><year>2023</year></date><date date-type="rev-recd"><day>5</day><month>1</month><year>2024</year></date><date date-type="accepted"><day>7</day><month>1</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>10</day><month>01</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>30</day><month>01</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-10-22 11:25:20.353"><day>22</day><month>10</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 The Authors</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><sec><title>Background</title><p>Ritonavir is one of the most potent CYP3A4 inhibitor currently on the market, and is often used together with other antiviral drugs to increase their bioavailability and efficacy. Paxlovid, consisting of nirmatrelvir and ritonavir, was approved for the treatment of COVID-19. As previous studies regarding the use of ritonavir during pregnancy were limited to ex-vivo experiments and systemic safety data, to fully explore the detailed pharmacokinetics of ritonavir in pregnant rats&#8217; blood and conceptus, an analytical method consisted of multi-microdialysis coupled with UHPLC-MS/MS were developed to analyze the pharmacokinetics of ritonavir, both as a component of Paxlovid and by itself. 17 days pregnant female Sprague-Dawley rats were randomly split into three experimental group: normal dosage of ritonavir alone (7&#160;mg&#160;kg<sup>&#8722;1</sup>), normal dosage of Paxlovid (ritonavir 7&#160;mg&#160;kg<sup>&#8722;1</sup>&#160;+&#160;nirmatrelvir 15&#160;mg&#160;kg<sup>&#8722;1</sup>), and 3&#215; dosage of ritonavir (21&#160;mg&#160;kg<sup>&#8722;1</sup>).</p></sec><sec><title>Results</title><p>3&#215; dosage of ritonavir produced a more than 3&#215; increase in rats&#8217; blood and placenta. Transfer rate of ritonavir to the placenta, amniotic fluid, and fetus were determined to be 20.7%, 13.8%, and 4.7% respectively. Concentration of ritonavir in the placenta, amniotic fluid, and fetus did not significantly go down after 8&#160;h.</p></sec><sec><title>Significance</title><p>Overall, ritonavir's metabolism was not influenced by the presence of nirmatrelvir in pregnant rats. A 3&#215; increase in dosage produced a concentration of roughly 4&#215;, most likely a result of ritonavir's auto-inhibition effect on cytochrome P450 proteins. Accumulation of ritonavir is possible in placenta, amniotic fluid, and fetus.</p></sec></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><p><fig id="undfig1" position="anchor" orientation="portrait"><alt-text id="alttext0010">Image 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ga1.jpg"/></fig></p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Microdialysis</kwd><kwd>Ritonavir</kwd><kwd>Paxlovid</kwd><kwd>Pharmacokinetic</kwd><kwd>Pregnancy</kwd><kwd>Placenta barrier</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0010">Ritonavir, a potent protease inhibitor, was originally developed for the treatment of HIV, and approved by the US Food and Drug administration between 1995 and 1997 [<xref rid="bib1" ref-type="bibr">1</xref>,<xref rid="bib2" ref-type="bibr">2</xref>]. As one of the most potent cytochrome P450 (CYP) 3A4 inhibitor currently in clinical use, ritonavir is commonly combined with other antiviral drugs involved in CYP3A4 metabolism pathway to boost their bioavailability and efficacy [<xref rid="bib3" ref-type="bibr">3</xref>], for the treatment of HIV, hepatitis C, and more recently COVID-19 [<xref rid="bib4" ref-type="bibr">[4]</xref>, <xref rid="bib5" ref-type="bibr">[5]</xref>, <xref rid="bib6" ref-type="bibr">[6]</xref>, <xref rid="bib7" ref-type="bibr">[7]</xref>]. At the start of the pandemic efforts were made to find suitable treatment, including the use of well-known antiviral combination lopinavir/ritonavir in a limited clinical trial, where both drugs&#8217; pharmacokinetic parameters were carefully analyzed [<xref rid="bib8" ref-type="bibr">8</xref>]. In order to contain the severity of COVID-19 symptoms, Pfizer combined ritonavir with second generation protease inhibitor, nirmatrelvir, forming the co-package anti-viral drug Paxlovid, originally approved by the U.S. Food and Drug Administration (FDA) under Emergency Use Authorization in December 2021, and fully approved for adult patients in May 2023 [<xref rid="bib9" ref-type="bibr">9</xref>,<xref rid="bib10" ref-type="bibr">10</xref>]. Aside from CYP3A4, ritonavir also exhibits inhibitory effect on P-glycoprotein, as shown by randomized placebo-controlled crossover study involving pre-treatment of ritonavir while monitoring digoxin distribution and elimination [<xref rid="bib11" ref-type="bibr">11</xref>].</p><p id="p0015">Previous studies regarding the use of ritonavir during pregnancy were limited to <italic toggle="yes">ex-vivo</italic> transplacental transfer rate [<xref rid="bib12" ref-type="bibr">12</xref>] and systemic safety [<xref rid="bib4" ref-type="bibr">4</xref>]. These techniques are somewhat limiting as e<italic toggle="yes">x-vivo</italic> transplacental transfer rate could not measure the transfer ratio into the fetus, and systemic safety can only be conducted after a sizable population had already taken the medication; while it was determined that ritonavir can passes the blood-placenta barrier and was systemically safe, conflicting information exists regarding the use of Paxlovid during pregnancy and breastfeeding. Clinical case review involving forty-seven pregnant patients revealed that no significant increase in serious adverse effect was observed through Paxlovid's treatment, but resulted in unexpectedly high rate of caesarean birth [<xref rid="bib13" ref-type="bibr">13</xref>]; while the European Medicines Agency advised against using Paxlovid during pregnancy and breastfeeding [<xref rid="bib14" ref-type="bibr">14</xref>].</p><p id="p0020">In order to determine the transplacental transfer ratio into the conceptus, our laboratory has made efforts in conventional sampling techniques [<xref rid="bib15" ref-type="bibr">15</xref>,<xref rid="bib16" ref-type="bibr">16</xref>], as well as microdialysis [<xref rid="bib17" ref-type="bibr">[17]</xref>, <xref rid="bib18" ref-type="bibr">[18]</xref>, <xref rid="bib19" ref-type="bibr">[19]</xref>, <xref rid="bib20" ref-type="bibr">[20]</xref>]. Microdialysis is a technique that uses probes with semipermeable membrane to sample endogenous and exogenous substances [<xref rid="bib21" ref-type="bibr">[21]</xref>, <xref rid="bib22" ref-type="bibr">[22]</xref>, <xref rid="bib23" ref-type="bibr">[23]</xref>]. It allows for the continuous monitoring of drugs in its protein unbound, pharmacologically active form, and can be utilized for the study of drug absorption, distribution, metabolism, and elimination (ADME) [<xref rid="bib24" ref-type="bibr">24</xref>]. In addition, the technique of microdialysis has the advantage of measuring drugs at specific sites, with detailed time profiles within a single experimental animal or human [<xref rid="bib25" ref-type="bibr">25</xref>]. The ability to monitor different sites simultaneously on the same experimental animal, makes microdialysis an ideal technique to study the pharmacokinetics of transplacental transfer of drug into the conceptus.</p><p id="p0025">Different analytical methods have been developed to analyze ritonavir, including liquid chromatography coupled with photodiode array [<xref rid="bib26" ref-type="bibr">26</xref>] or mass spectrometry [<xref rid="bib27" ref-type="bibr">[27]</xref>, <xref rid="bib28" ref-type="bibr">[28]</xref>, <xref rid="bib29" ref-type="bibr">[29]</xref>]; thin layer chromatography [<xref rid="bib30" ref-type="bibr">30</xref>], and spectrofluorometric detection [<xref rid="bib31" ref-type="bibr">31</xref>]. For this experiment, ultra-high-performance liquid chromatography (UHPLC) coupled with tandem mass spectrometry (MS/MS) was chosen for its good specificity and sensitivity, ease of new method development, and high throughput [<xref rid="bib32" ref-type="bibr">32</xref>], at the same time allowing for less sample input compared to high performance liquid chromatography (HPLC). Gas chromatography is more suitable for small, thermally stable, and volatile molecules [<xref rid="bib33" ref-type="bibr">33</xref>], neither applies to ritonavir [<xref rid="bib34" ref-type="bibr">34</xref>]. In terms of detection method, MS/MS allows for the structural identification of compounds, allowing for excellent sensitivity and specificity [<xref rid="bib32" ref-type="bibr">32</xref>]. One disadvantage of MS/MS is that the analytical method requires the irreversible destruction of analytes, making recovery impossible; however, this does not affect our experiment.</p><p id="p0030">We hypothesized that ritonavir's distribution is hindered by the blood-placenta barrier, and its concentration would decrease as blood travel past the barrier. In this study, a multiple microdialysis model coupled with UHPLC-MS/MS was developed to fully explore the detailed pharmacokinetics of ritonavir into the conceptus, both administered alone and as a component of Paxlovid.</p></sec><sec id="sec2"><label>2</label><title>Materials, method, and instrumentations</title><sec id="sec2.1"><label>2.1</label><title>Chemicals and reagents</title><p id="p0035">Components of Paxlovid were sourced separately: ritonavir from Cayman Chemical (Ann Arbor, MI, USA) and nirmatrelvir from MedChemExpress (Monmouth Junction, NJ, USA). Citric acid, sodium citrate, D-(+)-glucose, and sodium chloride were purchased from Sigma-Aldrich Chemicals (St. Louis, MO, USA). LCMS grade acetonitrile was supplied by J.T. Baker (Avantor Performance Materials, LLC, Radnor, PA, USA). LC grade methanol was made by Macron Fine Chemicals (Avantor Performance Materials, LLC, Radnor, PA, USA). Type I water (Millipore, Bedford, MA, USA) was used throughout the experiment, including UHPLC-MS/MS analysis. Ritonavir was dissolved in 100% methanol to prepare a standard solution (1&#160;mg&#160;mL<sup>&#8722;1</sup>), and subsequently diluted to generate a gradient series for standard curves. The anticoagulant citrate dextrose (ACD) solution utilized in this experiment composed of 3.5&#160;mM citric acid, 7.5&#160;mM sodium citrate, and 13.6&#160;mM D-(+)-glucose.</p></sec><sec id="sec2.2"><label>2.2</label><title>Analytical instruments and method validation</title><p id="p0040">Samples were analyzed using Ultra-High-Performance Liquid Chromatography &#8211; tandem Mass Spectrometry (UHPLC-MS/MS, 8030, Shimadzu, Kyoto Japan). The UHPLC system consisted of UHPLC pump (LC-20AD XR), autosampler (SIL-20AC XR), online degasser (DGU-20A3), communication bus module (CBM-20A), column oven (CTO-20A), and triple quadruple mass spectrometer (LCMS-8030). UHPLC analysis of ritonavir was validated according to Bioanalytical Method Validation Guidance for Industry released by the U.S Food and Drug Administration in May 2018 [<xref rid="bib35" ref-type="bibr">35</xref>]. Namely, the stability of short-term benchtop, autosampler, repeated freeze-thaw, and long-term freezing, as well as intra and inter-day accuracy and precision were verified. Matrix effect of our experimental procedures were analyzed. For the microdialysis experiment, probe recoveries for different probe types were also determined.</p></sec><sec id="sec2.3"><label>2.3</label><title>Experimental animals</title><p id="p0045">Pregnant female Sprague-Dawley rats (17&#160;&#177;&#160;2 days pregnant, 300&#160;&#177;&#160;50&#160;g) were obtained from National Yang Ming Chiao Tung University Animal Center, Taipei, Taiwan. Rats were housed in 12&#160;h light/dark cycle; laboratory rodent diet 5001 (PMI Feeds, Richmond, IN, USA) and water were given <italic toggle="yes">ad libitum</italic> up until 12&#160;h before surgery, at which point food was removed while water remained. The animal study protocol was approved by the Institutional Animal Care and Use Committee of National Yang Ming Chiao Tung University (IACUC No. 1110605, June 20th, 2022) and performed according to the National Research Council guidelines.</p></sec><sec id="sec2.4"><label>2.4</label><title>Microdialysis instruments and probe design</title><p id="p0050">The microdialysis system consisted of a microinjection pump (CMA/100, CMA, Stockholm, Sweden), 2.5&#160;mL micro-syringes (Ito Corporation, Fuji, Japan), sample collectors (CMA/142 and CMA/470, CMA, Stockholm, Sweden), and self-made microdialysis probe of varying design to best suit the sampling environments. Both rigid and flexible microdialysis probes were developed based on previous reports [<xref rid="bib36" ref-type="bibr">36</xref>]. Namely, a semi-permeable membrane (outer diameter 150&#160;&#956;m, molecular weight cut-off 13,000&#160;Da; Spectrum, Laguna Hills, CA, USA) was chosen to construct the active length of the probe. The blood probes had 1&#160;cm of membrane serving as its active length, and the probes for conceptus (fetus, placenta, and amniotic fluid) had an active length of 0.5&#160;cm. All tubing connections, as well as the tip of the membrane were sealed with epoxy glue at least 24&#160;h before experiment to allow for drying.</p></sec><sec id="sec2.5"><label>2.5</label><title>Animal grouping and surgical procedures</title><p id="p0055">Experimental animals were divided into 3 groups: human-equivalent dosage ritonavir 7&#160;mg&#160;kg<sup>&#8722;1</sup>, human-equivalent dosage Paxlovid consisting of ritonavir 7&#160;mg&#160;kg<sup>&#8722;1</sup> and nirmatrelvir 15&#160;mg&#160;kg<sup>&#8722;1</sup>, and 3&#215; ritonavir dosage 21&#160;mg&#160;kg<sup>&#8722;1</sup> to examine dosage dependent pharmacokinetics relations. The experimental rats were anesthetized using urethane (1&#160;g&#160;kg<sup>&#8722;1</sup>, i. p.). After anesthesia, the fur around the surgical sites were shaved off, and disinfected with 75% alcohol before proceeding with the surgical procedures as follows. First, an incision was made on the inner-left thigh of the rat to expose left femoral vein. A catheter tube made with polyethylene tube &#8211; 50 (PE-50) was implanted for intravenous (i.v.) drug administration. Following that, an incision was made on the right side of the neck to expose right jugular vein. A custom-made blood microdialysis probe was implanted toward the heart to collect dialysate from venous blood. Following the jugular vein, a roughly 3&#160;cm long incision was made on the midline of the abdomen to expose the embryonic vesicles. Vesicles were pulled out and carefully laid on gauze, and a 23-gauge needle was used to puncture holes in the embryonic vesicles for probes insertion of the conceptus (fetus, placenta, and amniotic fluid). Gauze were used to cover the exposed embryonic vesicles and kept moist with normal saline throughout the experiment to prevent drying.</p></sec><sec id="sec2.6"><label>2.6</label><title>Drug administration and sample collection</title><p id="p0060">Following surgical procedures and probe implantations, the probes were perfused for 1&#160;h with perfusate at a flow rate of 2&#160;&#956;L&#160;min<sup>&#8722;1</sup>. Anticoagulant citrate dextrose (ACD) solution was used as perfusate for all sampling sites. Drug (ritonavir 7 or 21&#160;mg&#160;kg<sup>&#8722;1</sup>, i.v.; and Paxlovid consisting of ritonavir 7&#160;mg&#160;kg<sup>&#8722;1</sup> and nirmatrelvir 15&#160;mg&#160;kg<sup>&#8722;1</sup>, i.v.) was administered through the femoral vein catheter after the hour-long perfusion period, depicting time 0; at which point sample collection also began. Samples were continuously collected and stored at 20&#160;min intervals for a total period of 8&#160;h, 20&#160;&#956;L of methanol was added to each sample vials to increase ritonavir's solubility, and subsequently stored at &#8722;20&#160;&#176;C until further analysis.</p></sec><sec id="sec2.7"><label>2.7</label><title>Statistical analysis</title><p id="p0065">Pharmacokinetic related parameters of the target drug were analyzed using WinNonlin software (version 1.1; Scientific Consulting Inc., Apex, NC, USA). Curve fitting comparison of compartmental models was performed using Akaike's information criterion (AIC) [<xref rid="bib37" ref-type="bibr">37</xref>]. SigmaPlot (version 11.0; Systat Software, London, UK) was used to plot the concentration-time curves. SPSS Statistics (version 22.0; IBM Corp., Armonk, NY, USA) was utilized to process statistics. Data were analyzed by one-way ANOVA with post-hoc Tukey HSD. A p value&#160;&lt;&#160;0.05 indicated statistically significant difference. All data are expressed as mean&#160;&#177;&#160;standard deviation (SD).</p></sec></sec><sec id="sec3"><label>3</label><title>Results</title><sec id="sec3.1"><label>3.1</label><title>UHPLC-MS/MS optimization</title><p id="p0070">Trials were conducted to optimize the UHPLC-MS/MS analytical parameters. Tandem Quadrupole Mass Spectrometer settings were optimized for ES&#160;+&#160;mode, with a collision energy of &#8722;20&#160;eV, interface voltage at 3.5&#160;kV, nebulizing gas flow of 3.0&#160;L&#160;min<sup>&#8722;1</sup>, the parameters resulted in parent to product ion transition of 721&#160;&#8594;&#160;296&#160;<italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> for ritonavir, as seen in <xref rid="fig1" ref-type="fig">Fig. 1</xref>.<fig id="fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Molecular structure and UHPLC-MS/MS single ion monitoring (SIM) chromatogram of ritonavir, showing the peaks of precursor ion and major product ion at <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 721 &#8594; 296.</p></caption><alt-text id="alttext0015">Fig. 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p><p id="p0075">Maximum peak area was obtained with a mobile phase consisted of (A) 0.1% formic acid in water and (B) acetonitrile. In order to sufficiently separate of ritonavir within the microdialysis samples, 20&#160;mL of methanol was added for each 40&#160;mL samples, and a 4-min gradient profile was developed as follows: starting with B at 30%, maintain for 0.5&#160;min, then raise B to 85% by 1.0&#160;min, drop B to 75% by 2.0&#160;min, and maintain 75% to 3.0&#160;min, finally drop B to 30% by 3.5&#160;min and maintain until 4.0&#160;min. The retention time of ritonavir was 2.5&#160;min, and the lower limit of quantitation was determined to be 0.1&#160;ng&#160;mL<sup>&#8722;1</sup>.</p></sec><sec id="sec3.2"><label>3.2</label><title>Method validation</title><p id="p0080">Method validation was performed to ensure the accuracy and repeatability of our experimental procedure. Sample stability for benchtop, auto-sampler, long-term freezing, and repeated freeze-thaw were validated, and confirmed to be within the acceptable value (<xref rid="tbl1" ref-type="table">Table 1</xref>).<table-wrap position="float" id="tbl1" orientation="portrait"><label>Table 1</label><caption><p>Stability validation of ritonavir in dialysates of pregnant rat blood, placenta, fetus, and amniotic fluid.</p></caption><alt-text id="alttext0035">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Concentration (ng mL<sup>&#8722;1</sup>)</th><th colspan="1" rowspan="1">Auto-Sampler (%)</th><th colspan="1" rowspan="1">Benchtop (%)</th><th colspan="1" rowspan="1">3&#215; Freeze-Thaw Cycle (%)</th><th colspan="1" rowspan="1">Long-term Storage (%)</th></tr></thead><tbody><tr><td colspan="5" align="left" rowspan="1">Blood</td></tr><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">94.21&#160;&#177;&#160;3.69</td><td align="left" colspan="1" rowspan="1">102.73&#160;&#177;&#160;5.47</td><td align="left" colspan="1" rowspan="1">95.58&#160;&#177;&#160;1.38</td><td align="left" colspan="1" rowspan="1">97.62&#160;&#177;&#160;3.05</td></tr><tr><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">96.61&#160;&#177;&#160;0.87</td><td align="left" colspan="1" rowspan="1">101.12&#160;&#177;&#160;5.00</td><td align="left" colspan="1" rowspan="1">98.56&#160;&#177;&#160;0.97</td><td align="left" colspan="1" rowspan="1">97.21&#160;&#177;&#160;0.71</td></tr><tr><td colspan="5" align="left" rowspan="1">Placenta</td></tr><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">97.17&#160;&#177;&#160;2.29</td><td align="left" colspan="1" rowspan="1">97.66&#160;&#177;&#160;1.89</td><td align="left" colspan="1" rowspan="1">99.18&#160;&#177;&#160;2.34</td><td align="left" colspan="1" rowspan="1">94.42&#160;&#177;&#160;0.92</td></tr><tr><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">96.13&#160;&#177;&#160;2.25</td><td align="left" colspan="1" rowspan="1">96.46&#160;&#177;&#160;2.55</td><td align="left" colspan="1" rowspan="1">97.31&#160;&#177;&#160;1.32</td><td align="left" colspan="1" rowspan="1">97.66&#160;&#177;&#160;0.28</td></tr><tr><td colspan="5" align="left" rowspan="1">Fetus</td></tr><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">95.80&#160;&#177;&#160;4.14</td><td align="left" colspan="1" rowspan="1">97.38&#160;&#177;&#160;9.39</td><td align="left" colspan="1" rowspan="1">94.93&#160;&#177;&#160;1.84</td><td align="left" colspan="1" rowspan="1">95.91&#160;&#177;&#160;0.62</td></tr><tr><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">92.13&#160;&#177;&#160;3.21</td><td align="left" colspan="1" rowspan="1">95.45&#160;&#177;&#160;1.62</td><td align="left" colspan="1" rowspan="1">98.85&#160;&#177;&#160;0.53</td><td align="left" colspan="1" rowspan="1">98.95&#160;&#177;&#160;0.73</td></tr><tr><td colspan="5" align="left" rowspan="1">Amniotic fluid</td></tr><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">95.55&#160;&#177;&#160;7.82</td><td align="left" colspan="1" rowspan="1">91.73&#160;&#177;&#160;3.62</td><td align="left" colspan="1" rowspan="1">97.55&#160;&#177;&#160;1.67</td><td align="left" colspan="1" rowspan="1">96.69&#160;&#177;&#160;2.59</td></tr><tr><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">95.87&#160;&#177;&#160;2.59</td><td align="left" colspan="1" rowspan="1">86.94&#160;&#177;&#160;7.37</td><td align="left" colspan="1" rowspan="1">94.76&#160;&#177;&#160;1.43</td><td align="left" colspan="1" rowspan="1">98.42&#160;&#177;&#160;2.72</td></tr></tbody></table><table-wrap-foot><fn><p>Auto-sampler and benchtop samples were left at respective area for 6&#160;h before testing. Freeze-thaw cycles were repeated 3 times, with each freezing cycle at &#8722;20&#160;&#176;C lasting for at least 12&#160;h before testing. In Long-term storage the samples were frozen at &#8722;20&#160;&#176;C for 30 days before thawing and testing. Data expressed as mean&#160;&#177;&#160;standard deviation. n&#160;=&#160;3.</p></fn></table-wrap-foot></table-wrap></p><p id="p0085">Intraday and interday accuracy and precision validation of our analytical methods were also performed and confirmed to be within acceptable range, detail can be seen in <xref rid="tbl2" ref-type="table">Table 2</xref>. Matrix effect was determined to be roughly 20% across all sample sites, details presented in <xref rid="tbl3" ref-type="table">Table 3</xref>. The recovery rate of the self-made blood and conceptus probes were determined to be 5.01% and 2.65% respectively (<xref rid="tbl4" ref-type="table">Table 4</xref>).<table-wrap position="float" id="tbl2" orientation="portrait"><label>Table 2</label><caption><p>Intraday and interday accuracy and precision validation of ritonavir in dialysates of pregnant rat blood, placenta, fetus, and amniotic fluid.</p></caption><alt-text id="alttext0040">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Nominal Concentration (ng mL<sup>&#8722;1</sup>)</th><th colspan="3" rowspan="1">Intraday<hr/></th><th colspan="3" rowspan="1">Interday<hr/></th></tr><tr><th colspan="1" rowspan="1">Observed Concentration (ng mL<sup>&#8722;1</sup>)</th><th colspan="1" rowspan="1">Accuracy (%)</th><th colspan="1" rowspan="1">Precision (%)</th><th colspan="1" rowspan="1">Observed Concentration (ng mL<sup>&#8722;1</sup>)</th><th colspan="1" rowspan="1">Accuracy (%)</th><th colspan="1" rowspan="1">Precision (%)</th></tr></thead><tbody><tr><td colspan="7" align="left" rowspan="1">Blood</td></tr><tr><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0.105&#160;&#177;&#160;0.004</td><td align="left" colspan="1" rowspan="1">5.02</td><td align="left" colspan="1" rowspan="1">3.52</td><td align="left" colspan="1" rowspan="1">0.093&#160;&#177;&#160;0.010</td><td align="left" colspan="1" rowspan="1">&#8722;6.71</td><td align="left" colspan="1" rowspan="1">10.22</td></tr><tr><td align="left" colspan="1" rowspan="1">0.5</td><td align="left" colspan="1" rowspan="1">0.480&#160;&#177;&#160;0.140</td><td align="left" colspan="1" rowspan="1">&#8722;4.05</td><td align="left" colspan="1" rowspan="1">2.91</td><td align="left" colspan="1" rowspan="1">0.497&#160;&#177;&#160;0.001</td><td align="left" colspan="1" rowspan="1">&#8722;0.67</td><td align="left" colspan="1" rowspan="1">0.29</td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">4.88&#160;&#177;&#160;0.30</td><td align="left" colspan="1" rowspan="1">&#8722;2.46</td><td align="left" colspan="1" rowspan="1">6.07</td><td align="left" colspan="1" rowspan="1">5.10&#160;&#177;&#160;0.10</td><td align="left" colspan="1" rowspan="1">2.05</td><td align="left" colspan="1" rowspan="1">1.97</td></tr><tr><td align="left" colspan="1" rowspan="1">50</td><td align="left" colspan="1" rowspan="1">50.12&#160;&#177;&#160;1.12</td><td align="left" colspan="1" rowspan="1">0.24</td><td align="left" colspan="1" rowspan="1">2.23</td><td align="left" colspan="1" rowspan="1">50.00&#160;&#177;&#160;0.00</td><td align="left" colspan="1" rowspan="1">&#8722;0.0003</td><td align="left" colspan="1" rowspan="1">0.002</td></tr><tr><td colspan="7" align="left" rowspan="1">Placenta</td></tr><tr><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0.114&#160;&#177;&#160;0.015</td><td align="left" colspan="1" rowspan="1">13.51</td><td align="left" colspan="1" rowspan="1">13.31</td><td align="left" colspan="1" rowspan="1">0.097&#160;&#177;&#160;0.007</td><td align="left" colspan="1" rowspan="1">&#8722;2.85</td><td align="left" colspan="1" rowspan="1">7.47</td></tr><tr><td align="left" colspan="1" rowspan="1">0.5</td><td align="left" colspan="1" rowspan="1">0.517&#160;&#177;&#160;0.029</td><td align="left" colspan="1" rowspan="1">3.45</td><td align="left" colspan="1" rowspan="1">5.57</td><td align="left" colspan="1" rowspan="1">0.496&#160;&#177;&#160;0.012</td><td align="left" colspan="1" rowspan="1">&#8722;0.80</td><td align="left" colspan="1" rowspan="1">2.32</td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">5.04&#160;&#177;&#160;0.10</td><td align="left" colspan="1" rowspan="1">0.89</td><td align="left" colspan="1" rowspan="1">2.05</td><td align="left" colspan="1" rowspan="1">4.97&#160;&#177;&#160;0.04</td><td align="left" colspan="1" rowspan="1">&#8722;0.53</td><td align="left" colspan="1" rowspan="1">0.75</td></tr><tr><td align="left" colspan="1" rowspan="1">50</td><td align="left" colspan="1" rowspan="1">49.91&#160;&#177;&#160;0.65</td><td align="left" colspan="1" rowspan="1">&#8722;0.19</td><td align="left" colspan="1" rowspan="1">1.29</td><td align="left" colspan="1" rowspan="1">50.00&#160;&#177;&#160;0.01</td><td align="left" colspan="1" rowspan="1">0.01</td><td align="left" colspan="1" rowspan="1">0.01</td></tr><tr><td colspan="7" align="left" rowspan="1">Fetus</td></tr><tr><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0.109&#160;&#177;&#160;0.004</td><td align="left" colspan="1" rowspan="1">9.49</td><td align="left" colspan="1" rowspan="1">3.53</td><td align="left" colspan="1" rowspan="1">0.100&#160;&#177;&#160;0.010</td><td align="left" colspan="1" rowspan="1">&#8722;0.33</td><td align="left" colspan="1" rowspan="1">9.84</td></tr><tr><td align="left" colspan="1" rowspan="1">0.5</td><td align="left" colspan="1" rowspan="1">0.526&#160;&#177;&#160;0.015</td><td align="left" colspan="1" rowspan="1">5.27</td><td align="left" colspan="1" rowspan="1">2.88</td><td align="left" colspan="1" rowspan="1">0.496&#160;&#177;&#160;0.013</td><td align="left" colspan="1" rowspan="1">&#8722;0.77</td><td align="left" colspan="1" rowspan="1">2.72</td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">4.91&#160;&#177;&#160;0.10</td><td align="left" colspan="1" rowspan="1">&#8722;1.80</td><td align="left" colspan="1" rowspan="1">2.03</td><td align="left" colspan="1" rowspan="1">5.02&#160;&#177;&#160;0.03</td><td align="left" colspan="1" rowspan="1">0.36</td><td align="left" colspan="1" rowspan="1">0.56</td></tr><tr><td align="left" colspan="1" rowspan="1">50</td><td align="left" colspan="1" rowspan="1">49.10&#160;&#177;&#160;0.79</td><td align="left" colspan="1" rowspan="1">&#8722;1.80</td><td align="left" colspan="1" rowspan="1">1.62</td><td align="left" colspan="1" rowspan="1">50.00&#160;&#177;&#160;0.002</td><td align="left" colspan="1" rowspan="1">&#8722;0.003</td><td align="left" colspan="1" rowspan="1">0.004</td></tr><tr><td colspan="7" align="left" rowspan="1">Amniotic fluid</td></tr><tr><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">0.117&#160;&#177;&#160;0.005</td><td align="left" colspan="1" rowspan="1">16.95</td><td align="left" colspan="1" rowspan="1">4.62</td><td align="left" colspan="1" rowspan="1">0.973&#160;&#177;&#160;0.013</td><td align="left" colspan="1" rowspan="1">&#8722;2.75</td><td align="left" colspan="1" rowspan="1">13.78</td></tr><tr><td align="left" colspan="1" rowspan="1">0.5</td><td align="left" colspan="1" rowspan="1">0.545&#160;&#177;&#160;0.016</td><td align="left" colspan="1" rowspan="1">8.97</td><td align="left" colspan="1" rowspan="1">2.95</td><td align="left" colspan="1" rowspan="1">0.501&#160;&#177;&#160;0.017</td><td align="left" colspan="1" rowspan="1">0.11</td><td align="left" colspan="1" rowspan="1">3.49</td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">5.13&#160;&#177;&#160;0.08</td><td align="left" colspan="1" rowspan="1">2.62</td><td align="left" colspan="1" rowspan="1">1.59</td><td align="left" colspan="1" rowspan="1">5.00&#160;&#177;&#160;0.03</td><td align="left" colspan="1" rowspan="1">&#8722;0.06</td><td align="left" colspan="1" rowspan="1">2.86</td></tr><tr><td align="left" colspan="1" rowspan="1">50</td><td align="left" colspan="1" rowspan="1">50.14&#160;&#177;&#160;0.88</td><td align="left" colspan="1" rowspan="1">0.28</td><td align="left" colspan="1" rowspan="1">1.76</td><td align="left" colspan="1" rowspan="1">49.99&#160;&#177;&#160;0.02</td><td align="left" colspan="1" rowspan="1">&#8722;0.01</td><td align="left" colspan="1" rowspan="1">0.05</td></tr></tbody></table><table-wrap-foot><fn><p>Precision&#160;=&#160;S.D./C<sub>obs</sub>, and accuracy = (C<sub>obs</sub> &#8722; C<sub>nom</sub>)/C<sub>nom</sub>. Observed concentration expressed as average&#160;&#177;&#160;standard deviation. n&#160;=&#160;3.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl3" orientation="portrait"><label>Table 3</label><caption><p>Matrix effect of ritonavir UHPLC-MS/MS analytical method of different rat analytes.</p></caption><alt-text id="alttext0045">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Nominal Concentration (ng mL<sup>&#8722;1</sup>)</th><th colspan="4" rowspan="1">Matrix effect (%)<hr/></th></tr><tr><th colspan="1" rowspan="1">Blood</th><th colspan="1" rowspan="1">Placenta</th><th colspan="1" rowspan="1">Fetus</th><th colspan="1" rowspan="1">Amniotic Fluid</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">0.5</td><td align="left" colspan="1" rowspan="1">20.95&#160;&#177;&#160;3.33</td><td align="left" colspan="1" rowspan="1">20.53&#160;&#177;&#160;3.13</td><td align="left" colspan="1" rowspan="1">18.80&#160;&#177;&#160;2.41</td><td align="left" colspan="1" rowspan="1">20.03&#160;&#177;&#160;2.79</td></tr><tr><td align="left" colspan="1" rowspan="1">10.</td><td align="left" colspan="1" rowspan="1">18.69&#160;&#177;&#160;2.28</td><td align="left" colspan="1" rowspan="1">20.09&#160;&#177;&#160;3.87</td><td align="left" colspan="1" rowspan="1">19.78&#160;&#177;&#160;1.75</td><td align="left" colspan="1" rowspan="1">19.82&#160;&#177;&#160;2.21</td></tr></tbody></table><table-wrap-foot><fn><p>Matrix effect is calculated by C<sub>sample</sub>/C<sub>ACD</sub>. A positive number indicates ion-enhancement effect. Anticoagulant citrate dextrose (ACD) consisted of citric acid 3.5&#160;mM, sodium citrate 7.5&#160;mM, and D-(+)-glucose 13.6&#160;mM in water. Data expressed as mean&#160;&#177;&#160;standard deviation. n&#160;=&#160;3.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl4" orientation="portrait"><label>Table 4</label><caption><p>Recovery of ritonavir for self-made blood and conceptus probes.</p></caption><alt-text id="alttext0050">Table 4</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Nominal Concentration (&#956;g mL<sup>&#8722;1</sup>)</th><th colspan="2" rowspan="1">Recovery (%)<hr/></th></tr><tr><th colspan="1" rowspan="1">Blood</th><th colspan="1" rowspan="1">Conceptus</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">4.44&#160;&#177;&#160;1.19</td><td align="left" colspan="1" rowspan="1">2.47&#160;&#177;&#160;0.89</td></tr><tr><td align="left" colspan="1" rowspan="1">1.0</td><td align="left" colspan="1" rowspan="1">5.58&#160;&#177;&#160;1.28</td><td align="left" colspan="1" rowspan="1">2.82&#160;&#177;&#160;1.00</td></tr><tr><td align="left" colspan="1" rowspan="1">average</td><td align="left" colspan="1" rowspan="1">5.01&#160;&#177;&#160;1.28</td><td align="left" colspan="1" rowspan="1">2.65&#160;&#177;&#160;0.94</td></tr></tbody></table><table-wrap-foot><fn><p>Anticoagulant citrate dextrose (ACD) solution was used as perfusate for the probes, it consisted of citric acid 3.5&#160;mM, sodium citrate 7.5&#160;mM, and D-(+)-glucose 13.6&#160;mM in water. Data expressed as mean&#160;&#177;&#160;standard deviation. n&#160;=&#160;6.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec3.3"><label>3.3</label><title>Pharmacokinetics of ritonavir</title><p id="p0090">Samples of typical UHPLC-MS/MS chromatograms of the experiment, including a blank dialysate, blank spiked with known concentration, and sample collected after drug administration for each probed organ (blood, placenta, amniotic fluid, and fetus) are shown in <xref rid="fig2" ref-type="fig">Fig. 2</xref>.<fig id="fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Typical UHPLC-MS/MS chromatogram of dialysate from (A) blank blood; (B) blank blood spiked with ritonavir 10&#160;ng&#160;mL<sup>&#8722;1</sup>; (C) blood sample collected 360&#160;min after ritonavir administration (21&#160;mg&#160;kg<sup>&#8722;1</sup>, i.v.), containing ritonavir 14.10&#160;ng&#160;mL<sup>&#8722;1</sup>; (D) blank placenta; (E) blank placenta spiked with ritonavir 0.5&#160;ng&#160;mL<sup>&#8722;1</sup>; (F) placenta sample collected 120&#160;min after Paxlovid administration (ritonavir 7&#160;mg&#160;kg<sup>&#8722;1</sup> with nirmatrelvir 15&#160;mg&#160;kg<sup>&#8722;1</sup>, i.v.), containing ritonavir 0.76&#160;ng&#160;mL<sup>&#8722;1</sup>; (G) blank amniotic fluid (AF); (H) blank AF spiked with ritonavir 1.0&#160;ng&#160;mL<sup>&#8722;1</sup>; (I) AF sample collected 120&#160;min after ritonavir administration (21&#160;mg&#160;kg<sup>&#8722;1</sup>, i.v.), containing ritonavir 1.15&#160;ng&#160;mL<sup>&#8722;1</sup>; (J) blank fetus; (K) blank fetus spiked with ritonavir 0.5&#160;ng&#160;mL<sup>&#8722;1</sup>; (L) fetus sample collected 120&#160;min after ritonavir administration (21&#160;mg&#160;kg<sup>&#8722;1</sup>, i.v.). Peak 1 depicts ritonavir signal with 2.5&#160;min retention time.</p></caption><alt-text id="alttext0020">Fig. 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="p0095"><xref rid="fig3" ref-type="fig">Fig. 3</xref> displays the concentration vs. time graph of the four tested locations. In blood, the concentration-over-time of ritonavir doesn't follow typical pharmacokinetic models, as the concentration didn't reached maximum until 1&#160;h after drug administration, as seen on <xref rid="fig3" ref-type="fig">Fig. 3</xref>a; this behavior was observed for all 3 experimental groups (<xref rid="fig3" ref-type="fig">Fig. 3</xref>a). Ritonavir could be observed in the placenta at 7&#160;mg&#160;kg<sup>&#8722;1</sup> (<xref rid="fig3" ref-type="fig">Fig. 3</xref>b); it was only observable in amniotic fluid and fetus at 21&#160;mg&#160;kg<sup>&#8722;1</sup> dosage level (<xref rid="fig3" ref-type="fig">Fig. 3</xref>c and d).<fig id="fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Ritonavir concentration vs time graph sampled from pregnant rats' (A) blood, (B) placenta, (C) amniotic fluid, and (D) fetus, after ritonavir (7&#160;mg&#160;kg<sup>&#8722;1</sup>, i.v.; 21&#160;mg&#160;kg<sup>&#8722;1</sup>, i.v.) and Paxlovid administration (ritonavir 7&#160;mg&#160;kg<sup>&#8722;1</sup>&#160;+&#160;nirmatrelvir 15&#160;mg&#160;kg<sup>&#8722;1</sup>, i.v.). n&#160;=&#160;6.</p></caption><alt-text id="alttext0025">Fig. 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p><p id="p0100">Pharmacokinetic (PK) parameters of the experiment are compiled in <xref rid="tbl5" ref-type="table">Table 5</xref>, and a column graph comparison compiled in <xref rid="fig4" ref-type="fig">Fig. 4</xref>. Overall, no significant difference was observed for any parameters between normal dosage of ritonavir (7&#160;mg&#160;kg<sup>&#8722;1</sup>) and Paxlovid (ritonavir 7&#160;mg&#160;kg<sup>&#8722;1</sup>&#160;+&#160;nirmatrelvir 15&#160;mg&#160;kg<sup>&#8722;1</sup>).<table-wrap position="float" id="tbl5" orientation="portrait"><label>Table 5</label><caption><p>Pharmacokinetic parameters of ritonavir as a component of Paxlovid in pregnant rat blood and conceptus, administered as normal Paxlovid dosage of ritonavir (7&#160;mg&#160;kg<sup>&#8722;1</sup>) with or without nirmatrelvir (15&#160;mg&#160;kg<sup>&#8722;1</sup>); and 3&#215; ritonavir dosage (21&#160;mg&#160;kg<sup>&#8722;1</sup>)<sup>.</sup></p></caption><alt-text id="alttext0055">Table 5</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Parameters</th><th colspan="1" rowspan="1">Ritonavir (7&#160;mg&#160;kg<sup>&#8722;1</sup>, i.v.)</th><th colspan="1" rowspan="1">Ritonavir (21&#160;mg&#160;kg<sup>&#8722;1</sup>, i.v.)</th><th colspan="1" rowspan="1">Paxlovid (Ritonavir 7&#160;mg&#160;kg<sup>&#8722;1</sup>&#160;+&#160;Nirmatrelvir 15&#160;mg&#160;kg<sup>&#8722;1</sup>, i.v.)</th></tr></thead><tbody><tr><td colspan="4" align="left" rowspan="1">blood</td></tr><tr><td align="left" colspan="1" rowspan="1">AUC (min &#956;g mL<sup>&#8722;1</sup>)</td><td align="left" colspan="1" rowspan="1">58.9&#160;&#177;&#160;23.3</td><td align="left" colspan="1" rowspan="1">235.8&#160;&#177;&#160;39.1**</td><td align="left" colspan="1" rowspan="1">56.0&#160;&#177;&#160;15.7</td></tr><tr><td align="left" colspan="1" rowspan="1">C<sub>max</sub> (&#956;g mL<sup>&#8722;1</sup>)</td><td align="left" colspan="1" rowspan="1">0.224&#160;&#177;&#160;0.083</td><td align="left" colspan="1" rowspan="1">0.996&#160;&#177;&#160;0.029**</td><td align="left" colspan="1" rowspan="1">0.240&#160;&#177;&#160;0.081</td></tr><tr><td align="left" colspan="1" rowspan="1">t<sub>1/2</sub> (min)</td><td align="left" colspan="1" rowspan="1">236&#160;&#177;&#160;42</td><td align="left" colspan="1" rowspan="1">253&#160;&#177;&#160;60*<sup>1</sup></td><td align="left" colspan="1" rowspan="1">175&#160;&#177;&#160;38</td></tr><tr><td align="left" colspan="1" rowspan="1">Cl (mL min<sup>&#8722;1</sup> kg<sup>&#8722;1</sup>)</td><td align="left" colspan="1" rowspan="1">104&#160;&#177;&#160;56</td><td align="left" colspan="1" rowspan="1">64&#160;&#177;&#160;16</td><td align="left" colspan="1" rowspan="1">108&#160;&#177;&#160;31</td></tr><tr><td align="left" colspan="1" rowspan="1">MRT (min)</td><td align="left" colspan="1" rowspan="1">200&#160;&#177;&#160;46</td><td align="left" colspan="1" rowspan="1">219&#160;&#177;&#160;21</td><td align="left" colspan="1" rowspan="1">195&#160;&#177;&#160;37</td></tr><tr><td colspan="4" align="left" rowspan="1">placenta</td></tr><tr><td align="left" colspan="1" rowspan="1">AUC (min &#956;g mL<sup>&#8722;1</sup>)</td><td align="left" colspan="1" rowspan="1">5.99&#160;&#177;&#160;0.91</td><td align="left" colspan="1" rowspan="1">48.13&#160;&#177;&#160;13.97**</td><td align="left" colspan="1" rowspan="1">6.13&#160;&#177;&#160;1.77</td></tr><tr><td align="left" colspan="1" rowspan="1">C<sub>max</sub> (&#956;g mL<sup>&#8722;1</sup>)</td><td align="left" colspan="1" rowspan="1">0.021&#160;&#177;&#160;0.004</td><td align="left" colspan="1" rowspan="1">0.189&#160;&#177;&#160;0.076**</td><td align="left" colspan="1" rowspan="1">0.027&#160;&#177;&#160;0.009</td></tr><tr><td align="left" colspan="1" rowspan="1">MRT (min)</td><td align="left" colspan="1" rowspan="1">285&#160;&#177;&#160;33</td><td align="left" colspan="1" rowspan="1">305&#160;&#177;&#160;30*<xref rid="tbl5fna" ref-type="table-fn">a</xref></td><td align="left" colspan="1" rowspan="1">230&#160;&#177;&#160;52</td></tr><tr><td align="left" colspan="1" rowspan="1">AUC<sub>placenta</sub>/AUC<sub>blood</sub></td><td align="left" colspan="1" rowspan="1">0.116&#160;&#177;&#160;0.049</td><td align="left" colspan="1" rowspan="1">0.207&#160;&#177;&#160;0.074*<xref rid="tbl5fnb" ref-type="table-fn">b</xref></td><td align="left" colspan="1" rowspan="1">0.118&#160;&#177;&#160;0.054</td></tr><tr><td colspan="4" align="left" rowspan="1">amniotic fluid</td></tr><tr><td align="left" colspan="1" rowspan="1">AUC (min &#956;g mL<sup>&#8722;1</sup>)</td><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">32.22&#160;&#177;&#160;15.23</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">C<sub>max</sub> (&#956;g mL<sup>&#8722;1</sup>)</td><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.174&#160;&#177;&#160;0.079</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">MRT (min)</td><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">307&#160;&#177;&#160;27</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">AUC<sub>amniotic fluid</sub>/AUC<sub>blood</sub></td><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.138&#160;&#177;&#160;0.064</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="4" align="left" rowspan="1">fetus</td></tr><tr><td align="left" colspan="1" rowspan="1">AUC (min &#956;g mL<sup>&#8722;1</sup>)</td><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">10.84&#160;&#177;&#160;5.74</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">C<sub>max</sub> (&#956;g mL<sup>&#8722;1</sup>)</td><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.042&#160;&#177;&#160;0.025</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">MRT (min)</td><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">263&#160;&#177;&#160;46</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">AUC<sub>fetus</sub>/AUC<sub>blood</sub></td><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.047&#160;&#177;&#160;0.023</td><td colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>Data expressed as mean&#160;&#177;&#160;standard deviation. Statistical significant differences were determined by one-way ANOVA with post-hoc Tukey HSD (n&#160;=&#160;6). *p&#160;&lt;&#160;0.05, **p&#160;&lt;&#160;0.01.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl5fna"><label>a</label><p id="ntpara0010">Compared to Paxlovid group.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl5fnb"><label>b</label><p id="ntpara0015">Compared to ritonavir 7&#160;mg&#160;kg<sup>&#8722;1</sup> group.</p></fn></table-wrap-foot></table-wrap><fig id="fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Column graph comparison of pharmacokinetic parameters between different experimental groups for (A) blood, and (B) placenta. *p&#160;&lt;&#160;0.05.</p></caption><alt-text id="alttext0030">Fig. 4</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p><p id="p0105">Non-compartment model was used to calculate the PK parameters of blood. Area under curve (AUC) for normal dosage of ritonavir and Paxlovid group were 58.9&#160;&#177;&#160;23.3&#160;min&#160;&#956;g mL<sup>&#8722;1</sup> and 56.0&#160;&#177;&#160;15.7&#160;min&#160;&#956;g mL<sup>&#8722;1</sup> respectively, while 3&#215; dosage of ritonavir produced an over 4&#215; increase to 235.8&#160;&#177;&#160;39.1&#160;min&#160;&#956;g mL<sup>&#8722;1</sup>. The same trend was observed in maximum concentration (C<sub>max</sub>), from normal ritonavir dosage and Paxlovid's 0.224&#160;&#177;&#160;0.083&#160;&#956;g&#160;mL<sup>&#8722;1</sup> and 0.240&#160;&#177;&#160;0.081 respectively, to 0.996&#160;&#177;&#160;0.029&#160;&#956;g&#160;mL<sup>&#8722;1</sup> at 3&#215; ritonavir dosage. No significant differences were observed between the PK parameters of normal dosage ritonavir group and Paxlovid group.</p><p id="p0110">In placenta, significant increase in AUC and C<sub>max</sub> was again observed in 3&#215; ritonavir group compared to both normal dosage and Paxlovid group. AUC was 5.99&#160;&#177;&#160;0.91&#160;min&#160;&#956;g mL<sup>&#8722;1</sup> at normal dosage, 6.13&#160;&#177;&#160;1.77&#160;min&#160;&#956;g mL<sup>&#8722;1</sup> for Paxlovid group, and 48.13&#160;&#177;&#160;13.97&#160;min&#160;&#956;g mL<sup>&#8722;1</sup> at 3&#215; ritonavir dosage. C<sub>max</sub> went from 0.021&#160;&#177;&#160;0.004&#160;&#956;g&#160;mL<sup>&#8722;1</sup> of normal dosage ritonavir, 0.027&#160;&#177;&#160;0.009&#160;&#956;g&#160;mL<sup>&#8722;1</sup> for Paxlovid, to 0.189&#160;&#177;&#160;0.076&#160;&#956;g&#160;mL<sup>&#8722;1</sup> observed in the 3&#215; ritonavir dosage group. Significant difference for mean retention time was observed between 3&#215; dosage group compared to Paxlovid group, at 305&#160;&#177;&#160;30&#160;min and 230&#160;&#177;&#160;52&#160;min respectively; and significant difference for AUC ratio between placenta and blood, i.e. the placenta transfer rate, was observed between normal ritonavir dosage and 3&#215; dosage group, being 0.116&#160;&#177;&#160;0.049 and 0.207&#160;&#177;&#160;0.074 respectively. When comparing 3&#215; dosage to Paxlovid group, the p value fell just outside the significance range at 0.051.</p><p id="p0115">At 7&#160;mg&#160;kg<sup>&#8722;1</sup> dosage level, ritonavir could not be detected with our experimental method in amniotic fluid and fetus, and at 3&#215; dosage level, transfer rate to amniotic fluid was 0.138&#160;&#177;&#160;0.064, and fetus at 0.047&#160;&#177;&#160;0.023.</p></sec></sec><sec id="sec4"><label>4</label><title>Discussion</title><p id="p0120">Ritonavir, a protease inhibitor originally developed for the treatment of HIV, is now frequently used as a booster in combination with other antiviral drugs due to its prominent inhibitory effect on CYP3A4.</p><p id="p0125">While samples collected from microdialysis typically required no pre-treatment for UHPLC-MS/MS analyzation, we found that ritonavir's water solubility to be too poor to remain stable, and the introduction of methanol to the perfusate successfully resolved this issue. This allowed for accurate quantification of ritonavir in pregnant rats' blood and conceptus simultaneously, making the determination of transfer ratio of ritonavir from blood into fetus and amniotic fluid possible, allowing for further pharmacokinetic studies.</p><p id="p0130">The dosage of ritonavir (7&#160;mg&#160;kg<sup>&#8722;1</sup>) and Paxlovid (ritonavir 7&#160;mg&#160;kg<sup>&#8722;1</sup>&#160;+&#160;nirmatrelvir 15&#160;mg&#160;kg<sup>&#8722;1</sup>) for the experiment was calculated by combining dosage conversion based on the body surface area method [<xref rid="bib38" ref-type="bibr">38</xref>] of the clinical recommended dosage of Paxlovid (ritonavir 150&#160;mg&#160;kg<sup>&#8722;1</sup>&#160;+&#160;nirmatrelvir 300&#160;mg&#160;kg<sup>&#8722;1</sup>) [<xref rid="bib39" ref-type="bibr">39</xref>], and the oral bioavailability of ritonavir (70% [<xref rid="bib40" ref-type="bibr">40</xref>]) and nirmatrelvir (50% [<xref rid="bib41" ref-type="bibr">41</xref>]).</p><p id="p0135">Method validation was performed to ensure the stability and reproducibility of the experiment. Ritonavir has been found to be stable throughout the analytical procedure, both low and high concentrations changed minimally while under typical experimental environments (<xref rid="tbl1" ref-type="table">Table 1</xref>); and that our experiment was highly reproducible (<xref rid="tbl2" ref-type="table">Table 2</xref>).</p><p id="p0140">The concentration vs time graph for ritonavir in blood followed an atypical curve, the concentration did not reach maximum until 1&#160;h after drug administration (<xref rid="fig3" ref-type="fig">Fig. 3</xref>a), likely due to the auto-inhibition effect of ritonavir and CYP3A4 [<xref rid="bib42" ref-type="bibr">42</xref>]. Our results showed that ritonavir's PK parameters isn't significantly influenced by the presence of nirmatrelvir in pregnant rats (<xref rid="tbl5" ref-type="table">Table 5</xref>, <xref rid="fig3" ref-type="fig">Fig. 3</xref>, <xref rid="fig4" ref-type="fig">Fig. 4</xref>A), indicating that ritonavir's metabolism isn't influenced by nirmatrelvir's presence. As ritonavir's primary function in Paxlovid is to boost the efficacy of nirmatrelvir [<xref rid="bib43" ref-type="bibr">43</xref>], this makes regulating nirmatrelvir's effective concentration in blood simpler.</p><p id="p0145">On the other hand, when the dosage of ritonavir (7&#160;mg&#160;kg<sup>&#8722;1</sup>) was increased by 3&#215; (21&#160;mg&#160;kg<sup>&#8722;1</sup>), a 4&#215; increase for AUC in blood was observed, from 58.9&#160;&#177;&#160;23.3&#160;min&#160;&#956;g mL<sup>&#8722;1</sup> to 235.8&#160;&#177;&#160;39.1&#160;min&#160;&#956;g mL<sup>&#8722;1</sup>, and a 4.4&#215; increase was observed for C<sub>max</sub>, from 0.224&#160;&#177;&#160;0.083&#160;&#956;g&#160;mL<sup>&#8722;1</sup> to 0.996&#160;&#177;&#160;0.029&#160;&#956;g&#160;mL<sup>&#8722;1</sup> (<xref rid="tbl5" ref-type="table">Table 5</xref>, <xref rid="fig4" ref-type="fig">Fig. 4</xref>A). This non-linear increase suggests a positive feedback in the auto-inhibition effect, specifically the increased inhibition of CYP3A4 leading to even higher concentration of ritonavir available in the bloodstream.</p><p id="p0150">Previously reported transplacental transfer rate of ritonavir at therapeutic dosage was 18.7% [<xref rid="bib12" ref-type="bibr">12</xref>], more than that of normal dosage of ritonavir and Paxlovid, at 0.116&#160;&#177;&#160;0.049 and 0.118&#160;&#177;&#160;0.054 respectively (<xref rid="tbl5" ref-type="table">Table 5</xref>, <xref rid="fig4" ref-type="fig">Fig. 4</xref>B). This discrepancy could be attributed to the difference in transporter expression between species [<xref rid="bib44" ref-type="bibr">44</xref>,<xref rid="bib45" ref-type="bibr">45</xref>]. The placental transfer rate significantly increased to 0.207&#160;&#177;&#160;0.074 for the 3&#215; ritonavir dosage group when compared to normal dosage group, and fall just short of significance when compared to Paxlovid group (<xref rid="tbl5" ref-type="table">Table 5</xref>, <xref rid="fig4" ref-type="fig">Fig. 4</xref>B). Previous study examining ritonavir and placental transfer protein concluded that it only exhibit weak interaction with multidrug resistance-associated proteins 2 (ABCC2) [<xref rid="bib46" ref-type="bibr">46</xref>], it is possible the increased concentration overwhelmed the transport protein, leading to an increased transfer ratio.</p><p id="p0155">The transfer ratio into the amniotic and fetus at normal dosage level of ritonavir was undetectable for our analytical method, and for the 3&#215; ritonavir dosage group was 13.8% and 4.7% respectively (<xref rid="tbl5" ref-type="table">Table 5</xref>, <xref rid="fig4" ref-type="fig">Fig. 4</xref>B). This trend is consistent with similar study into drug transfer ratio of placenta, amniotic fluid, and fetus [<xref rid="bib47" ref-type="bibr">[47]</xref>, <xref rid="bib48" ref-type="bibr">[48]</xref>, <xref rid="bib49" ref-type="bibr">[49]</xref>]. Comparing transfer ratio of the three conceptus organs suggests that placenta does provide a barrier effect and hinders ritonavir transfer into the conceptus.</p><p id="p0160">However, closer inspection of the concentration vs time graph seems to suggest a cumulative effect of ritonavir in the conceptus of pregnant rats, more prominent in the amniotic fluid and fetus (<xref rid="fig3" ref-type="fig">Fig. 3</xref>b, c, d). However, the low hydrophilic characteristics of ritonavir resulted in a probe recovery rate on the lower side, which potentially prevented closer study of the transfer ratio into the conceptus without raising drug dosage. Further studies would be required to evaluate the extent of ritonavir cumulation and its effect on newborns.</p></sec><sec id="sec5"><label>5</label><title>Conclusion</title><p id="p0165">Due to the recent Covid-19 pandemic, ritonavir combined with nirmatrelvir was approved by the FDA for emergency use. While previous studies explored <italic toggle="yes">ex-vivo</italic> transplacental transfer and systemic safety of ritonavir, this study explored the details of <italic toggle="yes">in-vivo</italic> transplacental transfer rate of ritonavir into the conceptus of rats. Blood-placenta barrier is effective at reducing ritonavir transfer into the womb, but not completely. Moreover, concentration vs. time graph suggests that ritonavir can accumulate in placenta, amniotic fluid, and fetus. Further study will be required to evaluate the extend of this cumulation effect.</p></sec><sec id="sec6"><title>Additional information</title><p id="p0170">No additional information is available for this paper.</p></sec><sec sec-type="data-availability" id="sec7"><title>Data availability statement</title><p id="p0175">Data are available from the corresponding author upon reasonable request.</p></sec><sec id="sec8"><title>CRediT authorship contribution statement</title><p id="p0180"><bold>Chung-Kai Sun:</bold> Writing - original draft, Validation, Methodology, Investigation, Formal analysis, Data curation. <bold>Wan-Hsin Lee:</bold> Validation, Methodology, Formal analysis. <bold>Muh-Hwa Yang:</bold> Conceptualization, Funding acquisition, Project administration, Writing - review &amp; editing. <bold>Tung-Hu Tsai:</bold> Writing - review &amp; editing, Writing - original draft, Supervision, Project administration, Investigation, Conceptualization.</p></sec><sec sec-type="COI-statement"><title>Declaration of competing interest</title><p id="p0185">The authors declare that they have no known competing financial interests nor personal relationships that could have influence the work reported in this paper.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Hsu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Granneman</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Bertz</surname><given-names>R.J.</given-names></name></person-group><article-title>Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents</article-title><source>Clin. Pharmacokinet.</source><volume>35</volume><year>1998</year><fpage>275</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.2165/00003088-199835040-00002</pub-id><pub-id pub-id-type="pmid">9812178</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Greenblatt</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Harmatz</surname><given-names>J.S.</given-names></name></person-group><article-title>Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies</article-title><source>Br. J. Clin. Pharmacol.</source><volume>80</volume><year>2015</year><fpage>342</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1111/bcp.12668</pub-id><pub-id pub-id-type="pmid">25923589</pub-id><pub-id pub-id-type="pmcid">PMC4574820</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Loos</surname><given-names>N.H.C.</given-names></name><name name-style="western"><surname>Beijnen</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Schinkel</surname><given-names>A.H.</given-names></name></person-group><article-title>The mechanism-based inactivation of CYP3A4 by ritonavir: what mechanism?</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><fpage>23</fpage><pub-id pub-id-type="doi">10.3390/ijms23179866</pub-id><pub-id pub-id-type="pmid">36077262</pub-id><pub-id pub-id-type="pmcid">PMC9456214</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Pasley</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hermes</surname><given-names>A.</given-names></name><name name-style="western"><surname>d'Amico</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nilius</surname><given-names>A.</given-names></name></person-group><article-title>Safety and efficacy of lopinavir/ritonavir during pregnancy: a systematic review</article-title><source>AIDS Rev.</source><volume>15</volume><year>2013</year><fpage>38</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">23449228</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>T.</given-names></name><name name-style="western"><surname>McNicholl</surname><given-names>I.</given-names></name><name name-style="western"><surname>Custodio</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Szwarcberg</surname><given-names>J.</given-names></name><name name-style="western"><surname>Piontkowsky</surname><given-names>D.</given-names></name></person-group><article-title>Drug interactions with cobicistat- or ritonavir-boosted elvitegravir</article-title><source>AIDS Rev.</source><volume>18</volume><year>2016</year><fpage>101</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">27196356</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>von Hentig</surname><given-names>N.</given-names></name></person-group><article-title>Atazanavir/ritonavir: a review of its use in HIV therapy</article-title><source>Drugs Today</source><volume>44</volume><year>2008</year><fpage>103</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1358/dot.2008.44.2.1137107</pub-id><pub-id pub-id-type="pmid">18389089</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Lamb</surname><given-names>Y.N.</given-names></name></person-group><article-title>Nirmatrelvir plus ritonavir: first approval</article-title><source>Drugs</source><volume>82</volume><year>2022</year><fpage>585</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1007/s40265-022-01692-5</pub-id><pub-id pub-id-type="pmid">35305258</pub-id><pub-id pub-id-type="pmcid">PMC8933659</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>L&#234;</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Jaquet</surname><given-names>P.</given-names></name><name name-style="western"><surname>Patrier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wicky</surname><given-names>P.-H.</given-names></name><name name-style="western"><surname>Le Hingrat</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Veyrier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kauv</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sonneville</surname><given-names>R.</given-names></name><name name-style="western"><surname>Visseaux</surname><given-names>B.</given-names></name><name name-style="western"><surname>Laou&#233;nan</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients</article-title><source>J. Antimicrob. Chemother.</source><volume>75</volume><year>2020</year><fpage>2657</fpage><lpage>2660</lpage><pub-id pub-id-type="doi">10.1093/jac/dkaa261</pub-id><pub-id pub-id-type="pmid">32688374</pub-id><pub-id pub-id-type="pmcid">PMC7454557</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="book" id="sref9"><person-group person-group-type="author"><collab>Paxlovid</collab></person-group><part-title>In LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</part-title><year>2012</year><publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name><publisher-loc>Bethesda (MD)</publisher-loc><pub-id pub-id-type="pmid">31643176</pub-id></element-citation></ref><ref id="bib10"><label>10</label><mixed-citation publication-type="other" id="sref10">USFDA. FDA Approves First Oral Antiviral for Treatment of COVID-19 in Adults. Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-antiviral-treatment-covid-19-adults" id="intref0010">https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-antiviral-treatment-covid-19-adults</ext-link> (accessed on November 2nd, 2023)..</mixed-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tayrouz</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Riedel</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Burhenne</surname><given-names>J.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mikus</surname><given-names>G.</given-names></name><name name-style="western"><surname>Haefeli</surname><given-names>W.E.</given-names></name></person-group><article-title>Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers</article-title><source>Clin. Pharmacol. Ther.</source><volume>76</volume><year>2004</year><fpage>73</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.clpt.2004.02.008</pub-id><pub-id pub-id-type="pmid">15229466</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Gavard</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gil</surname><given-names>S.</given-names></name><name name-style="western"><surname>Peytavin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ceccaldi</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>C.</given-names></name><name name-style="western"><surname>Farinotti</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mandelbrot</surname><given-names>L.</given-names></name></person-group><article-title>Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model</article-title><source>Am. J. Obstet. Gynecol.</source><volume>195</volume><year>2006</year><fpage>296</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1016/j.ajog.2006.01.017</pub-id><pub-id pub-id-type="pmid">16678781</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Garneau</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Jones-Beatty</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ufua</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Mostafa</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Burd</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gebo</surname><given-names>K.A.</given-names></name></person-group><article-title>Analysis of clinical outcomes of pregnant patients treated with nirmatrelvir and ritonavir for acute SARS-CoV-2 infection</article-title><source>JAMA Netw. Open</source><volume>5</volume><year>2022</year><object-id pub-id-type="publisher-id">e2244141</object-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.44141</pub-id><pub-id pub-id-type="pmcid">PMC9709643</pub-id><pub-id pub-id-type="pmid">36445705</pub-id></element-citation></ref><ref id="bib14"><label>14</label><mixed-citation publication-type="other" id="sref14">EMA issues advice on use of Paxlovid (PF-07321332 and ritonavir) for the treatment of COVID-19: rolling review starts in parallel. Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/news/ema-issues-advice-use-paxlovid-pf-07321332-ritonavir-treatment-covid-19-rolling-review-starts" id="intref0015">https://www.ema.europa.eu/en/news/ema-issues-advice-use-paxlovid-pf-07321332-ritonavir-treatment-covid-19-rolling-review-starts</ext-link> (accessed on 16 June).</mixed-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Yen</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>T.H.</given-names></name></person-group><article-title>Chemical analysis and transplacental transfer of oseltamivir and oseltamivir carboxylic acid in pregnant rats</article-title><source>PLoS One</source><volume>7</volume><year>2012</year><object-id pub-id-type="publisher-id">e46062</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0046062</pub-id><pub-id pub-id-type="pmcid">PMC3463610</pub-id><pub-id pub-id-type="pmid">23056234</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>Y.N.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>T.H.</given-names></name></person-group><article-title>Preclinical transplacental transfer and pharmacokinetics of fipronil in rats</article-title><source>Drug Metab. Dispos.</source><volume>48</volume><year>2020</year><fpage>886</fpage><lpage>893</lpage><pub-id pub-id-type="doi">10.1124/dmd.120.000088</pub-id><pub-id pub-id-type="pmid">32723848</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>I.H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hsueh</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>T.H.</given-names></name></person-group><article-title>Blood-placental barrier transfers and pharmacokinetics of unbound morphine in pregnant rats with multiple microdialysis systems</article-title><source>ACS Pharmacol. Transl. Sci.</source><volume>4</volume><year>2021</year><fpage>1588</fpage><lpage>1597</lpage><pub-id pub-id-type="doi">10.1021/acsptsci.1c00142</pub-id><pub-id pub-id-type="pmid">34661076</pub-id><pub-id pub-id-type="pmcid">PMC8506599</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>I.H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dalley</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>T.H.</given-names></name></person-group><article-title>Trans-placental transfer of nicotine: modulation by organic cation transporters</article-title><source>Biomed. Pharmacother.</source><volume>145</volume><year>2022</year><object-id pub-id-type="publisher-id">112489</object-id><pub-id pub-id-type="doi">10.1016/j.biopha.2021.112489</pub-id><pub-id pub-id-type="pmid">34915670</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>I.H.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Dalley</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>T.H.</given-names></name></person-group><article-title>Biotransformation and transplacental transfer of the anti-viral remdesivir and predominant metabolite, GS-441524 in pregnant rats</article-title><source>EBioMedicine</source><volume>81</volume><year>2022</year><object-id pub-id-type="publisher-id">104095</object-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2022.104095</pub-id><pub-id pub-id-type="pmcid">PMC9166662</pub-id><pub-id pub-id-type="pmid">35671622</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>I.H.</given-names></name><name name-style="western"><surname>Hsueh</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Dalley</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>T.H.</given-names></name></person-group><article-title>Pharmacokinetics and transplacental transfer of codeine and codeine metabolites from Papaver somniferum L</article-title><source>J. Ethnopharmacol.</source><volume>298</volume><year>2022</year><object-id pub-id-type="publisher-id">115623</object-id><pub-id pub-id-type="doi">10.1016/j.jep.2022.115623</pub-id><pub-id pub-id-type="pmid">36007718</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Verbeeck</surname><given-names>R.K.</given-names></name></person-group><article-title>Blood microdialysis in pharmacokinetic and drug metabolism studies</article-title><source>Adv. Drug Deliv. Rev.</source><volume>45</volume><year>2000</year><fpage>217</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/S0169-409X(00)00110-1</pub-id><pub-id pub-id-type="pmid">11108975</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Bourne</surname><given-names>J.A.</given-names></name></person-group><article-title>Intracerebral microdialysis: 30 years as a tool for the neuroscientist</article-title><source>Clin. Exp. Pharmacol. Physiol.</source><volume>30</volume><year>2003</year><fpage>16</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1046/j.1440-1681.2003.03789.x</pub-id><pub-id pub-id-type="pmid">12542448</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Tsai</surname><given-names>T.-H.</given-names></name></person-group><article-title>Assaying protein unbound drugs using microdialysis techniques</article-title><source>J. Chromatogr. B</source><volume>797</volume><year>2003</year><fpage>161</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/j.jchromb.2003.08.036</pub-id><pub-id pub-id-type="pmid">14630148</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="book" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Tsai</surname><given-names>T.-H.</given-names></name></person-group><part-title>Chapter 6.5 Assaying protein-unbound drugs using microdialysis techniques</part-title><person-group person-group-type="editor"><name name-style="western"><surname>Westerink</surname><given-names>B.H.C.</given-names></name><name name-style="western"><surname>Cremers</surname><given-names>T.I.F.H.</given-names></name></person-group><series>Handbook of Behavioral Neuroscience</series><volume>vol. 16</volume><year>2006</year><publisher-name>Elsevier</publisher-name><fpage>573</fpage><lpage>587</lpage></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="book" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Hammarlund-Udenaes</surname><given-names>M.</given-names></name></person-group><part-title>Chapter 6.6 Microdialysis for characterization of PK/PD relationships</part-title><person-group person-group-type="editor"><name name-style="western"><surname>Westerink</surname><given-names>B.H.C.</given-names></name><name name-style="western"><surname>Cremers</surname><given-names>T.I.F.H.</given-names></name></person-group><series>Handbook of Behavioral Neuroscience</series><volume>vol. 16</volume><year>2006</year><publisher-name>Elsevier</publisher-name><fpage>589</fpage><lpage>600</lpage></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Imam</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Batubara</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Gamal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Abdelazim</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Almrasy</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Ramzy</surname><given-names>S.</given-names></name></person-group><article-title>Adjusted green HPLC determination of nirmatrelvir and ritonavir in the new FDA approved co-packaged pharmaceutical dosage using supported computational calculations</article-title><source>Sci. Rep.</source><volume>13</volume><year>2023</year><fpage>137</fpage><pub-id pub-id-type="doi">10.1038/s41598-022-26944-y</pub-id><pub-id pub-id-type="pmid">36599900</pub-id><pub-id pub-id-type="pmcid">PMC9811874</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Han</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Simultaneous quantification of nirmatrelvir/ritonavir in human serum by LC-HRMS</article-title><source>J. Pharm. Biomed. Anal.</source><volume>237</volume><year>2024</year><object-id pub-id-type="publisher-id">115796</object-id><pub-id pub-id-type="doi">10.1016/j.jpba.2023.115796</pub-id><pub-id pub-id-type="pmid">37839266</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Hendrikx</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Rosing</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schinkel</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Schellens</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Beijnen</surname><given-names>J.H.</given-names></name></person-group><article-title>Combined quantification of paclitaxel, docetaxel and ritonavir in human feces and urine using LC-MS/MS</article-title><source>Biomed. Chromatogr.</source><volume>28</volume><year>2014</year><fpage>302</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1002/bmc.3021</pub-id><pub-id pub-id-type="pmid">23996474</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Hendrikx</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Hillebrand</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Thijssen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rosing</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schinkel</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Schellens</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Beijnen</surname><given-names>J.H.</given-names></name></person-group><article-title>A sensitive combined assay for the quantification of paclitaxel, docetaxel and ritonavir in human plasma using liquid chromatography coupled with tandem mass spectrometry</article-title><source>J. Chromatogr., B: Anal. Technol. Biomed. Life Sci.</source><volume>879</volume><year>2011</year><fpage>2984</fpage><lpage>2990</lpage><pub-id pub-id-type="doi">10.1016/j.jchromb.2011.08.034</pub-id><pub-id pub-id-type="pmid">21920826</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Imam</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Abdelazim</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Batubara</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Gamal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Almrasy</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Ramzy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Khojah</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hasanin</surname><given-names>T.H.A.</given-names></name></person-group><article-title>Simultaneous green TLC determination of nirmatrelvir and ritonavir in the pharmaceutical dosage form and spiked human plasma</article-title><source>Sci. Rep.</source><volume>13</volume><year>2023</year><fpage>6165</fpage><pub-id pub-id-type="doi">10.1038/s41598-023-32904-x</pub-id><pub-id pub-id-type="pmid">37061601</pub-id><pub-id pub-id-type="pmcid">PMC10105527</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Imam</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Abdelazim</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Ramzy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Almrasy</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Gamal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Batubara</surname><given-names>A.S.</given-names></name></person-group><article-title>Higher sensitive selective spectrofluorometric determination of ritonavir in the presence of nirmatrelvir: application to new FDA approved co-packaged COVID-19 pharmaceutical dosage and spiked human plasma</article-title><source>BMC Chem.</source><volume>17</volume><year>2023</year><fpage>120</fpage><pub-id pub-id-type="doi">10.1186/s13065-023-01030-0</pub-id><pub-id pub-id-type="pmid">37735663</pub-id><pub-id pub-id-type="pmcid">PMC10514966</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.V.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bluth</surname><given-names>M.H.</given-names></name></person-group><article-title>Liquid chromatography-tandem mass spectrometry: an emerging Technology in the toxicology laboratory</article-title><source>Clin. Lab. Med.</source><volume>36</volume><year>2016</year><fpage>635</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1016/j.cll.2016.07.001</pub-id><pub-id pub-id-type="pmid">27842783</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Maurer</surname><given-names>H.H.</given-names></name></person-group><article-title>Systematic toxicological analysis of drugs and their metabolites by gas chromatography-mass spectrometry</article-title><source>J. Chromatogr.</source><volume>580</volume><year>1992</year><fpage>3</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/0378-4347(92)80526-v</pub-id><pub-id pub-id-type="pmid">1400828</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Gambhir</surname><given-names>K.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jangir</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Mehrotra</surname><given-names>R.</given-names></name></person-group><article-title>Thermal stability and hydration behavior of ritonavir sulfate: a vibrational spectroscopic approach</article-title><source>J. Pharm. Anal.</source><volume>5</volume><year>2015</year><fpage>348</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1016/j.jpha.2015.05.001</pub-id><pub-id pub-id-type="pmid">29403949</pub-id><pub-id pub-id-type="pmcid">PMC5762246</pub-id></element-citation></ref><ref id="bib35"><label>35</label><mixed-citation publication-type="other" id="sref35">USFDA. Bioanalytical Method Validation Guidance for Industry. Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf" id="intref0020">https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf</ext-link> (accessed on November 15th, 2021)..</mixed-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Tsai</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Chou</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.F.</given-names></name></person-group><article-title>Measurement and pharmacokinetics of unbound 20(S)-camptothecin in rat blood and brain by microdialysis coupled to microbore liquid chromatography with fluorescence detection</article-title><source>J. Chromatogr. A</source><volume>870</volume><year>2000</year><fpage>221</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1016/s0021-9673(99)00854-7</pub-id><pub-id pub-id-type="pmid">10722080</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Yamaoka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Uno</surname><given-names>T.</given-names></name></person-group><article-title>Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations</article-title><source>J. Pharmacokinet. Biopharm.</source><volume>6</volume><year>1978</year><fpage>165</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1007/bf01117450</pub-id><pub-id pub-id-type="pmid">671222</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Reagan-Shaw</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nihal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>N.</given-names></name></person-group><article-title>Dose translation from animal to human studies revisited</article-title><source>FASEB J.</source><volume>22</volume><year>2008</year><fpage>659</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1096/fj.07-9574LSF</pub-id><pub-id pub-id-type="pmid">17942826</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><collab>Paxlovid for treatment of COVID-19</collab></person-group><source>Med. Lett. Drugs Ther.</source><volume>64</volume><year>2022</year><fpage>9</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">35134040</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="book" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Kubin</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Hammer</surname><given-names>S.M.</given-names></name></person-group><part-title>Chapter 145 - antiretroviral agents</part-title><person-group person-group-type="editor"><name name-style="western"><surname>Cohen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Opal</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Powderly</surname><given-names>W.G.</given-names></name></person-group><source>Infectious Diseases</source><edition>third ed.</edition><year>2010</year><publisher-name>Mosby</publisher-name><publisher-loc>London</publisher-loc><fpage>1434</fpage><lpage>1453</lpage></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Hung</surname><given-names>Y.-P.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.-C.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>C.-W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C.-C.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>P.-J.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>I.-L.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>W.-C.</given-names></name></person-group><article-title>Oral nirmatrelvir/ritonavir therapy for COVID-19: the dawn in the dark?</article-title><source>Antibiotics</source><volume>11</volume><year>2022</year><fpage>220</fpage><pub-id pub-id-type="pmid">35203821</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antibiotics11020220</pub-id><pub-id pub-id-type="pmcid">PMC8868411</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Eichbaum</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cortese</surname><given-names>M.</given-names></name><name name-style="western"><surname>Blank</surname><given-names>A.</given-names></name><name name-style="western"><surname>Burhenne</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mikus</surname><given-names>G.</given-names></name></person-group><article-title>Concentration effect relationship of CYP3A inhibition by ritonavir in humans</article-title><source>Eur. J. Clin. Pharmacol.</source><volume>69</volume><year>2013</year><fpage>1795</fpage><lpage>1800</lpage><pub-id pub-id-type="doi">10.1007/s00228-013-1530-8</pub-id><pub-id pub-id-type="pmid">23748748</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>R.S.P.</given-names></name><name name-style="western"><surname>Toussi</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Hackman</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Van Eyck</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pawlak</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kadar</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Innovative randomized phase I study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of nirmatrelvir</article-title><source>Clin. Pharmacol. Ther.</source><volume>112</volume><year>2022</year><fpage>101</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1002/cpt.2603</pub-id><pub-id pub-id-type="pmid">35388471</pub-id><pub-id pub-id-type="pmcid">PMC9087011</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name name-style="western"><surname>Staud</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cerveny</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ceckova</surname><given-names>M.</given-names></name></person-group><article-title>Pharmacotherapy in pregnancy; effect of ABC and SLC transporters on drug transport across the placenta and fetal drug exposure</article-title><source>J. Drug Target.</source><volume>20</volume><year>2012</year><fpage>736</fpage><lpage>763</lpage><pub-id pub-id-type="pmid">22994411</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/1061186X.2012.716847</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Bleasby</surname><given-names>K.</given-names></name><name name-style="western"><surname>Evers</surname><given-names>R.</given-names></name></person-group><article-title>Species differences in drug transporters and implications for translating preclinical findings to humans</article-title><source>Expet Opin. Drug Metabol. Toxicol.</source><volume>9</volume><year>2013</year><fpage>237</fpage><lpage>252</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/17425255.2013.741589</pub-id><pub-id pub-id-type="pmid">23256482</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Cerveny</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ptackova</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Durisova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Staud</surname><given-names>F.</given-names></name></person-group><article-title>Interactions of protease inhibitors atazanavir and ritonavir with ABCB1, ABCG2, and ABCC2 transporters: effect on transplacental disposition in rats</article-title><source>Reprod. Toxicol.</source><volume>79</volume><year>2018</year><fpage>57</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.reprotox.2018.05.008</pub-id><pub-id pub-id-type="pmid">29859254</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name name-style="western"><surname>van Lierde</surname><given-names>M.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>K.</given-names></name></person-group><article-title>Ritodrine concentrations in maternal and fetal serum and amniotic fluid</article-title><source>J. Perinat. Med.</source><volume>10</volume><year>1982</year><fpage>119</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1515/jpme.1982.10.2.119</pub-id><pub-id pub-id-type="pmid">7097468</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>Paulzen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Goecke</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Stingl</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Janssen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Stickeler</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gr&#252;nder</surname><given-names>G.</given-names></name><name name-style="western"><surname>Schoretsanitis</surname><given-names>G.</given-names></name></person-group><article-title>Pregnancy exposure to citalopram - therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood</article-title><source>Prog. Neuro-Psychopharmacol. Biol. Psychiatry</source><volume>79</volume><year>2017</year><fpage>213</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2017.06.030</pub-id><pub-id pub-id-type="pmid">28663113</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name name-style="western"><surname>Paulzen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Goecke</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Stickeler</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gr&#252;nder</surname><given-names>G.</given-names></name><name name-style="western"><surname>Schoretsanitis</surname><given-names>G.</given-names></name></person-group><article-title>Sertraline in pregnancy - therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood</article-title><source>J. Affect. Disord.</source><volume>212</volume><year>2017</year><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2017.01.019</pub-id><pub-id pub-id-type="pmid">28129551</pub-id></element-citation></ref></ref-list><sec id="appsec1"><title>Abbreviations</title><p id="p0195">
<def-list><def-item><term id="d0010">ACD</term><def><p id="p0200">anticoagulant citrate dextrose</p></def></def-item><def-item><term id="d0015">AUC</term><def><p id="p0205">area under curve</p></def></def-item><def-item><term id="d0020">CACD</term><def><p id="p0210">concentration in ACD solution</p></def></def-item><def-item><term id="d0025">C<sub>max</sub></term><def><p id="p0215">maximum concentration</p></def></def-item><def-item><term id="d0030">C<sub>nom</sub></term><def><p id="p0220">nominal concentration</p></def></def-item><def-item><term id="d0035">C<sub>obs</sub></term><def><p id="p0225">observed concentration</p></def></def-item><def-item><term id="d0040">C<sub>sample</sub></term><def><p id="p0230">concentration in blank sample</p></def></def-item><def-item><term id="d0045">Cl</term><def><p id="p0235">clearance</p></def></def-item><def-item><term id="d0050">MRT</term><def><p id="p0240">mean retention time</p></def></def-item><def-item><term id="d0055">t<sub>1/2</sub></term><def><p id="p0245">half life</p></def></def-item></def-list>
</p></sec><ack id="ack0010"><title>Acknowledgments</title><p id="p0190">This study was conducted as part of the PhD dissertation of Chung-Kai Sun. This study was supported in part by research grants from the National Science and Technology Council of Taiwan (NSTC 111-2113-M-A49-018 and NSTC 112-2321-B-A49-005) and a graduate student scholarship from the College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.</p></ack></back></article></pmc-articleset>